Table 10

Sensitivity analysis of net budget impact of ustekinumab per patient (€)
Year 1 Year 2 Year 3 Year 4 Year 5
Base case −443 −674 −786 −847 −900
Non-responders’ outpatient costs
−10% −443 −673 −785 −846 −899
+10% −444 −674 −786 −848 −901
Non-responders’ hospitalization costs
−10% −417 −647 −759 −820 −873
+10% −470 −700 −812 −874 −927
Ustekinumab share
−5% −340 −559 −671 −732 −785
+5% −547 −789 −901 −962 −1,015
−10% −254 −441 −552 −614 −665
+10% −648 −906 −1,018 −1,080 −1,133

Note: Negative values indicate budget savings.

Avgerinou et al.

Avgerinou et al. BMC Dermatology 2012 12:10   doi:10.1186/1471-5945-12-10

Open Data